Vera Therapeutics Secures FDA Accelerated Approval for TRUTAKNA in IgAN — Vera Therapeutics, Inc.

Event summary

Vera Therapeutics received FDA accelerated approval for TRUTAKNA to treat primary IgA nephropathy (IgAN) on August 10, 2026.
The company reported a net loss of $109.5 million for Q2 2026, up from $76.5 million in Q2 2025.
TRUTAKNA demonstrated a 46% reduction in proteinuria in the ORIGIN Phase 3 trial published in November 2025.
Vera Therapeutics anticipates submitting a supplemental Biologics License Application (sBLA) to the FDA in Q4 2026.

The big picture

Vera Therapeutics' FDA accelerated approval for TRUTAKNA positions it as a pioneer in treating IgAN, a progressive kidney disease with limited therapeutic options. The company's strategic focus on commercializing innovative therapies aligns with broader industry trends toward targeted treatments for rare diseases. However, managing financial losses and ensuring long-term regulatory compliance will be critical for sustained growth.

What we're watching

Regulatory Milestones: Whether the FDA's accelerated approval will lead to sustained market adoption of TRUTAKNA.
Financial Performance: How Vera Therapeutics will manage increasing net losses while advancing its commercial launch.
Clinical Efficacy: The impact of the ORIGIN 3 trial results on TRUTAKNA's potential full approval in 2027.